PRRT2 and breast carcinoma: In a more systematic in vitro approach, interference with different steps of EVs biogenesis in prostate and breast cancer cell lines, Kosgodage et al. confirmed that among a series of 11 inhibitors targeting various steps of EVs biogenesis, PAD inhibitors, as well as inhibitors of PKC (Bisindolylmaleimide-I), were the most powerful inhibitors in prostate and breast cancer cell lines [129].